every four weeks), and then at least every 6 12 months once the target has been achieved Probenecid (fully funded) and febuxostat (funded with Special Authority approval) are alternatives for patients who find allopurinol ineffective or intolerable
They are most valuable for patients who are already committed to lifestyle changes but need additional support to see consistent results
This led to research in the use of liraglutide, semaglutide and tirzepatide for the purpose of chronic weight management
Premium Everything in Free, plus broader older/future calendar browsing, projected Estimated Exposure scenarios, advanced summaries, clinician-ready PDF summaries, and deeper reporting tools
KATHERINE SAMARAS: People are vulnerable
Source: NEJM, 2023 Telehealth GLP-1 Access Expanding Rapidly The intersection of telehealth platforms and GLP-1 prescribing is one of the fastest-growing segments of digital health